Trousseau's syndrome triggered by an immune checkpoint blockade in a non-small cell lung cancer patient

Abstract

PD-1 blockade therapy activates T cells by blocking the interaction between PD-1 and PD-L1 and promotes IFN-γ and Th1 cytokine production. In turn, IFN-γ and Th1 cytokines produced by activated T cells promote TF synthesis in monocytes/macrophages, which results in hypercoagulability leading to thrombosis.

Keywords: Immune checkpoint blockade; Immune-related adverse event; Lung cancer; Tissue factor; Trousseau's syndrome.